The role and impact of religiousness/spirituality in determining physical well-being among survivors of breast cancer is not well understood.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
The latest breast cancer treatment regimens with detailed drug information such as pertuzamab with trastuzumab and docetaxel.
The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.
Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.
Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.
There are benefits and drawbacks to the public availability to DTC mutation tests.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26June 03, 2018
The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.
MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine TherapyJune 03, 2018
With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.
It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast CancerJune 03, 2018
Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Computer analysis is not better than human clinical evaluation when it comes to measuring breast densityMay 23, 2018
In the United States, the standard for monitoring breast density is through the Breast Imaging Reporting and Data System (BI-RADS). There has been recent concern regarding the reproducibility of this system, as there is subjectivity in the breast density estimated by radiologists.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.
Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer